David C Hastings - Net Worth and Insider Trading
David C Hastings Net Worth
The estimated net worth of David C Hastings is at least $1 Million dollars as of 2024-11-29. David C Hastings is the CFO of Incyte Corp and owns about 8,500 shares of Incyte Corp (INCY) stock worth over $641,325. David C Hastings is the CFO of Arbutus Biopharma Corp and owns about 181,907 shares of Arbutus Biopharma Corp (ABUS) stock worth over $631,217. David C Hastings is also the Director of SCYNEXIS Inc and owns about 3,183 shares of SCYNEXIS Inc (SCYX) stock worth over $4,361. Details can be seen in David C Hastings's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David C Hastings has not made any transactions after 2024-02-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of David C Hastings
David C Hastings Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David C Hastings owns 6 companies in total, including SCYNEXIS Inc (SCYX) , Entasis Therapeutics Holdings Inc (ETTX) , and Arbutus Biopharma Corp (ABUS) among others .
Click here to see the complete history of David C Hastings’s form 4 insider trades.
Insider Ownership Summary of David C Hastings
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SCYX | SCYNEXIS Inc | 2023-06-15 | director |
| ETTX | Entasis Therapeutics Holdings Inc | 2019-06-19 | director |
| ABUS | Arbutus Biopharma Corp | 2024-02-02 | Chief Financial Officer |
 | | 2017-01-26 | See Remarks |
| | 2014-06-05 | Exec VP & CFO |
| | 2023-01-01 | director |
David C Hastings Latest Holdings Summary
David C Hastings currently owns a total of 3 stocks. Among these stocks, David C Hastings owns 8,500 shares of Incyte Corp (INCY) as of June 5, 2014, with a value of $641,325 and a weighting of 50.23%. David C Hastings owns 181,907 shares of Arbutus Biopharma Corp (ABUS) as of February 2, 2024, with a value of $631,217 and a weighting of 49.43%. David C Hastings also owns 3,183 shares of SCYNEXIS Inc (SCYX) as of March 8, 2018, with a value of $4,361 and a weighting of 0.34%.
Latest Holdings of David C Hastings
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2014-06-05 | 8,500 | 75.45 | 641,325 |
| ABUS | Arbutus Biopharma Corp | 2024-02-02 | 181,907 | 3.47 | 631,217 |
| SCYX | SCYNEXIS Inc | 2018-03-08 | 3,183 | 1.37 | 4,361 |
Holding Weightings of David C Hastings
David C Hastings Form 4 Trading Tracker
According to the SEC Form 4 filings, David C Hastings has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 200,000 shares on June 5, 2014, which brought David C Hastings around $11 Million.
According to the SEC Form 4 filings, David C Hastings has made a total of 1 transactions in Arbutus Biopharma Corp (ABUS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Arbutus Biopharma Corp is the sale of 9,593 shares on February 2, 2024, which brought David C Hastings around $22,160.
According to the SEC Form 4 filings, David C Hastings has made a total of 0 transactions in SCYNEXIS Inc (SCYX) over the past 5 years. The most-recent trade in SCYNEXIS Inc is the acquisition of 1,183 shares on March 8, 2018, which cost David C Hastings around $20,000.
Insider Trading History of David C Hastings
- 1
David C Hastings Trading Performance
GuruFocus tracks the stock performance after each of David C Hastings's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David C Hastings is 27.38%. GuruFocus also compares David C Hastings's trading performance to market benchmark return within the same time period. The performance of stocks bought by David C Hastings within 3 months outperforms 5 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David C Hastings's insider trading performs compared to the benchmark.
Performance of David C Hastings
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 16.14 | | | | | |
| Relative Return to S&P 500(%) | 11.67 | | | | | |
David C Hastings Ownership Network
David C Hastings Owned Company Details
What does SCYNEXIS Inc do?
Who are the key executives at SCYNEXIS Inc?
David C Hastings is the director of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Medical Officer Gonzalez David Angulo , Chief Financial Officer Ivor Macleod , and General Counsel Scott Sukenick .
SCYNEXIS Inc (SCYX) Insider Trades Summary
Over the past 18 months, David C Hastings made no insider transaction in SCYNEXIS Inc (SCYX). Other recent insider transactions involving SCYNEXIS Inc (SCYX) include a net purchase of 20,000 shares made by Gonzalez David Angulo ,
In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 20,000 shares, with a net purchase of 20,000 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.
SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.
SCYNEXIS Inc Insider Transactions
David C Hastings Mailing Address
Above is the net worth, insider trading, and ownership report for David C Hastings. You might contact David C Hastings via mailing address: C/o Arbutus Biopharma, 100-8900 Glenlyon Parkway, Burnaby A1 V5j 5j8.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
